Clinical trials: Advanced Cancers, active
Hepatocellular Carcinoma (HCC)
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
- Trial name
- NCT06860490
- Testing
- Sintilimab, Bevacizumab Biosimilar, HAIC
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Fudan University
Advanced Solid Tumor, Metastatic Solid Tumor
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human Phase 1a/b, open-label, multicenter, dose escalation, optimization and expansion study of ISM5939 to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of ISM5939 in patients…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid Tumors
- Trial name
- NCT06724042
- Testing
- ISM5939, Cisplatin, Docetaxel
- Volunteers
- 159 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Advanced Solid Tumors
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has multiple parts.
- Trial name
- NCT07387068
- Testing
- GEN1079
- Where
- 12 sites in United States, Spain
- Volunteers
- 121 people
- Sponsor
- Genmab
Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07545213
- Testing
- SKB264
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Patients With Advanced Solid Tumors
Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors
This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.
- Trial name
- NCT07661797
- Testing
- LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)
- Volunteers
- 294 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
The purpose of this study is to test if the BG-92505 is safe and if it works in patients with advanced solid tumors when it is given on its own or in combination with anti-cancer agents.
- Trial name
- NCT07896460
- Testing
- BG-92505, Anti-Cancer Agent
- Volunteers
- 137 people
- Sponsor
- BeOne Medicines
Non-Small Cell Lung Cancer
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with…
- Trial name
- NCT07824882
- Testing
- HS-20093 for Injection, Adebrelimab Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Hansoh BioMedical R&D Company
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Breast Cancer
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor).
- Trial name
- NCT01872260
- Testing
- LEE011, Letrozole, BYL719
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 259 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC)
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii.
- Trial name
- NCT07075120
- Testing
- Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Hawaii
Advanced Solid Tumor
Study of SGN1 in Patients With Advanced Solid Tumor
Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors.
- Trial name
- NCT05038150
- Testing
- SGN1
- Where
- 9 sites in United States, China
- Volunteers
- 70 people
- Sponsor
- Guangzhou Sinogen Pharmaceutical Co., Ltd
Ovarian Cancer
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study.
- Trial name
- MIROC-1 (NCT03854110)
- Testing
- misetionamide (also known as GP-2250)
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Persevere Therapeutics Inc.
Malignant Neoplasm of Stomach, Unspecified
Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201
HER2 is highly expressed on the surface of several cancer types, including breast and gastric/gastroesophageal junction (GEJ) cancers.
- Trial name
- NCT07333820
- Testing
- AB-201 Dose escalation
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Yonsei University
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1340 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1340 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm
- Trial name
- NCT07890246
- Testing
- IM-1340
- Volunteers
- 200 people
- Sponsor
- Immunome, Inc.
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
- Trial name
- TMB-H (NCT06365840)
- Testing
- IMC-001
- Where
- 4 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
This is a Phase III clinical trial for patients with a specific type of advanced breast cancer that is HER2-negative and has a biomarker called "Homologous Recombination Deficiency (HRD)-positive." The study aims to compare the…
- Trial name
- NCT07371910
- Testing
- Chemotherapy/ADC Regimen, Fluorizoparib, Apatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Brain Metastasis From Advanced HER2-negative Breast Cancer
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and…
- Trial name
- NCT06839560
- Testing
- Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy, Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other…
- Conditions
- Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT04413123
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bradley A. McGregor, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.